David P Walling

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 6

Top Topics

Major Depressive Disorder

Estrogen Receptor

Top Venues

Clinical and translational science

Drug design, development and therapy

Therapeutic advances in psychopharmacology

JMIR mHealth and uHealth

This page only lists publications with an associated author ORCID identifier.

Publications

Swan Lin, Adrian Ionescu, Jessica Maynard-Scott, Mike Kennedy, David P Walling, Maura Furey, Jaskaran B Singh
Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults. Clinical and translational science 17 (5) (2024)
Swan Lin, Adrian Ionescu, Jessica Maynard-Scott, Mike Kennedy, David P Walling, Maura Furey, Jaskaran B Singh
Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults. Clinical and translational science 17 (5) (2024)
Swan Lin, Adrian Ionescu, Jessica Maynard-Scott, Mike Kennedy, David P Walling, Maura Furey, Jaskaran B Singh
Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults. Clinical and translational science 17 (5) (2024)
David P Walling, Howard A Hassman, Lourdes Anta, Lourdes Ochoa, Ignacio Ayani, Javier Martínez, Ibon Gutierro
The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study. Drug design, development and therapy 15 (2021)
Marjie L Hard, Angela Wehr, Lisa von Moltke, Yangchun Du, Sarah Farwick, David P Walling, John Sonnenberg
Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil. Therapeutic advances in psychopharmacology 9 (2019)
Earle E Bain, Laura Shafner, David P Walling, Ahmed A Othman, Christy Chuang-Stein, John Hinkle, Adam Hanina
Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR mHealth and uHealth 5 (2) (2017)